New FDA Update on Valsartan Recalls: FDA releases method for detection and quantification of both NDMA and NDEA - Drug Information Update

FDA is posting a redeveloped combined gas chromatography-mass spectrometry (GC/MS) headspace method for detecting the presence of impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in valsartan drug products.
FDA previously posted a GC/MS method for detection of NDMA in valsartan products. Upon detection of NDEA in valsartan products manufactured by Zhejiang Huahai Pharmaceuticals, FDA redeveloped the testing method so that it can be used to detect and quantify levels of both NDMA and NDEA. This method should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.
FDA is also working on a GC/MS direct injection method for detection of NDMA and NDEA. We will post the method when it is available. This will provide an additional option for regulators and industry to use to detect both impurities.

For more information, please visit: FDA Updates on Valsartan Recalls.
https://www.fda.gov/downloads/Drugs/DrugSafety/UCM623198.pdf?utm_campaign=FDA%20releases%20method%20for%20detection%20and%20quantification%20of%20both%20NDMA%20and%20NDEA&utm_medium=email&utm_source=Eloqua&elqTrackId=897562680fc04945b507443053909ae6&elq=63feda925c314219b2aafd11c32c9f55&elqaid=5451&elqat=1&elqCampaignId=4373